Sign inJoin waitlistJoin the waitlist

James Battiste

Associate Professor · University of Oklahoma College of Medicine

Credentials: · · · · ·

History

University of Oklahoma College of Medicine
Present

University of Texas Southwestern Medical Center
2010–2011
Neurology
University of Texas Southwestern Medical Center
2007–2010
Univ of Texas Southwestern Med Sch at Dallas
2003–2007

Research

Genetic fate mapping reveals that the caudal ganglionic eminence produces a large and diverse population of superficial cortical interneurons
Journal of Neuroscience · 2010 · 448 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3…
JAMA Oncology · 2023 · 399 citations
Mash1 specifies neurons and oligodendrocytes in the postnatal brain
The EMBO Journal · 2004 · 304 citations

MS
Michael Sughrue
29 papers
Andrew Conner
25 papers · 23 as a resident
CG
Chad Glenn
25 papers · 23 as a resident
Robert Briggs
24 papers · 2 as a resident
JB
Joshua Burks
20 papers · 20 as a resident
Cordell Baker
19 papers · 19 as a resident
DO
Daniel O'Donoghue
11 papers
Ian Dunn
10 papers · 1 as a fellow
MR
Meherzad Rahimi
8 papers
Phillip Bonney
7 papers · 2 as a resident
Christopher Graffeo
5 papers · 5 as a fellow
CS
Christen O'Neal Swann
3 papers · 3 as a resident

Grants

Mentoring Translational Cancer Research in Oklahoma
National Institute of General Medical Sciences · P20
Project lead · $857.1K · University of Oklahoma Hlth Sciences Ctr
2012–2023

Clinical trials

PARP Inhibition for Gliomas (PI-4G or π4g)
Principal investigator · Terminated · Phase 2
University of Oklahoma
2022–2024
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
Principal investigator · Active not recruiting · Phase 1
University of Oklahoma
2018–2026
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Principal investigator · Unknown · Phase 1
Oblato, Inc.
2012–2023
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2027